Hints and tips:
...However, Steensberg stressed his company, which joined forces with German pharma group Boehringer Ingelheim more than a decade ago to develop a weight loss drug that is now in late-stage trials, wanted to...
...German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate....
...Carinne Brouillon, Boehringer Ingelheim’s head of human pharma, said she expected to bring the drug to market in 2027 or 2028, making it the third drugmaker to commercialise the new kind of weight-loss drug...
...Survodutide, which Boehringer Ingelheim developed with Danish biotech Zealand Pharma, copies a hormone called GLP-1 to reduce appetite in the same way as the existing drugs....
...German pharma group Boehringer Ingelheim is commercialising a Zealand treatment for both obesity and liver disease that is set to launch by 2028....
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...As the lawsuits move towards trial, companies who sold branded versions of Zantac over the past 35 years — including GSK, Sanofi, Pfizer and Boehringer Ingelheim Pharmaceuticals — have denied that using...
...Boehringer Ingelheim, Europe’s biggest private drugmaker, hired Simone Menne as chief financial officer from airline Lufthansa....
...The move comes less than three years after Lilly bought Novartis’s animal health unit for $5.4bn and 10 months after it acquired an animal vaccines division from Boehringer Ingelheim, which helped the group...
...However, two other versions are now available: Canagliflozin, which is manufactured by Janssen, and Empagliflozin, developed jointly by Boehringer Ingelheim and Eli Lilly & Co, putting pressure on AstraZeneca...
...Even so, the big multinationals — under pressure to focus — have been hiving off their animal medicine arms: Novartis to Eli Lilly; Sanofi of France to Boehringer Ingelheim....
...Sanofi is being advised by Lazard and Boehringer Ingelheim by Rothschild and BofA Merrill Lynch....
...The same will be true of Boehringer as a maker of drugs for livestock and pets, where competitors include Zoetis, Eli Lilly and Merck & Co....
...Possible buyers include Zoetis and pharma groups that still have animal health divisions: Lilly, Bayer and possibly Boehringer Ingelheim, which is privately held....
...Scientists first identified the significance of CGRP in migraines in the 1980s, but earlier drugs developed by US-based Merck and Boehringer Ingelheim were abandoned amid signs that they caused liver damage...
...Eli Lilly has partnered with Boehringer Ingelheim to develop a “biosimilar” version of Lantus....
...Sanofi, Actavis and Boehringer Ingelheim were among other companies touted as contenders in the auction of privately-held Omega....
...But a so-called “biosimilar” developed by Eli Lilly and Boehringer Ingelheim was approved by European regulators last month and the pair are pushing for its entry into the US....
...Boehringer Ingelheim of Germany filed for information on InterMune’s products. Both rivals were developing similar compounds....
...Most of Vectura’s pipeline of drug formulations and new inhalers that have yet to come on the market have been licensed to Novartis, Boehringer Ingelheim, and Sandoz, the generics maker....
...The biggest private family-owned company in Europe, according to rankings prepared by the Financial Times and McKinsey last year, is Boehringer Ingelheim, a pharmaceuticals group with an estimated equity...
...Since it introduced tough new security measures in 2001, for example, Boehringer Ingelheim of Germany has identified more than 100 incidents of counterfeits of its products, which range from respiratory...
...Some indigenous players remain, such as Boehringer Ingelheim, whose products include heart and Aids treatments....
International Edition